<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/252490-method-of-sterilization by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:20:05 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 252490:METHOD OF STERILIZATION</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">METHOD OF STERILIZATION</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A method of sterilization of active pharmaceutical ingredients characterized in that wet mass comprising micronised active ingredient along with pharmaceutically acceptable excipient and one or more vehicle thereof is subjected to a temperature ranging 100-140 degree/C for 3-30 mins at variable pressure units. The present invention further discloses the process for preparation of sterile pharmaceutical formulation.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br>
FORM 2<br>
THE PATENT ACT 1970<br>
(39 of 1970)<br>
&amp;<br>
The Patents Rules, 2003<br>
COMPLETE SPECIFICATION<br>
	(Sec section 10 and rule!3)	<br>
1.	TITLE OF THE INVÉNTION:<br>
"Method of sterilization"<br>
2.	APPLICANT<br>
(a) NAME: CIPLA LTD.<br>
(b)NATIONALITY: Indian Company incorporated under the Indian<br>
Companies ACT, 1956<br>
(c) ADDRESS: 289, Bellasis Road, Mumbai Central, Mumbai - 400 008,<br>
Maharashtra, India.<br>
3.PREAMBLE TO THE DESCRÏPTION<br><br><br>
The following specification particularly describes the invention and the manner<br>
in which it is to be performed.	<br><br>
Technical field of invention:<br>
The present invention relates to an improved method of sterilization for steroids to be<br>
used in formulations that are required to be sterile.<br>
Background and prior art:<br>
Sterilization is a process performed to ensure that thefe is complete freedom from<br>
microbial contamination. Sterlisation is especially done for pharmaceutical formulations<br>
which are to be directly introduced into the body and its cavities. Such formulations<br>
explicitly include ophthalmic preparations, nasal preparations, ocular preparations,<br>
injectables, transdermal patches, depot preparations and the like. Such sterilized<br>
preparations involve two methods of preparations. First route is that the active ingrediënt<br>
is sterilized and the formulation is prepared aseptically or the final is prepared, packed in<br>
the desired container and then sterilized. The second route is known as terminal<br>
Sterilization technique.<br>
Certain formulations such as respules or aqueous nasal preparations, ophthalmic<br>
preparations and the like that involve steroids as the active ingrediënt are usually<br>
prepared in the first method as described above. The most important reason being that<br>
these formulations are usually packed in the container such as LDPE which are not<br>
suitable for terminal Sterilization.<br>
Several patents which disclose the method of Sterilization of the active ingrediënt. PT-A-<br>
69652 discloses the cold Sterilization of micronized gluctfcorticosteroids using mixtures<br>
of ethylene oxide and carbon dioxide, since, according to PT-A-69652, steroids in<br>
powder form are not stable at temperarures above60 C. Specific examples of<br>
glucorticosteroids are prednacindone, budesonide, dexamethasone and prednisolone, and<br>
salts, esters and fluoro derivatives thereof, including dexamethasone acetate,<br>
dexamethasone phosphate, prednisolone pivalate and 9-alphafluoro prednisolone.<br>
However, ethylene oxide is toxic and when it is used to sterilize glucocorticosteroids it<br>
2<br><br>
has been found that the residual amounts of the ethylene oxide contravene pharmaceutical<br>
guidelines, which require very low levels of residual ethylene oxide. Accordingly this<br>
method has been found to be unsuitable for producing therapeutically acceptable<br>
glucocorticosteroids and formulations thereof.<br>
US-A-3962430 discloses a method for the production of sterile isotonic solutions of<br>
medicina! agents, which comprises adding the agent to a saturated solution of sodium<br>
chloride in water at lOO C and then heating the mixture at 1OO-130 C. This method is not<br>
suitable for suspensions of fine particles of steroids, which are intended for inhalation<br>
because the water, and the heating and cooling involved, produce unfavorable changes in<br>
the size of the particles. Indeed it can lead to the formation of bridges between the fine<br>
particles producing large, hard aggregates, which will not deaggregate into the desired<br>
fine particles upon administration.<br>
A putative alternative is dry heat sterilization. According to the European Pharmacopoeia<br>
(1996, pp. 283-4) a normal heat sterilization process runs at l80o C for 30 min or at a<br>
minimum of!60°C for at least 2 hours. According to Pharmacopoeia Nordica (1964,<br>
pp. 16) such. sterilization can be carried out at 140°C for 3 hours. However at the<br>
temperatures of these processes glucocorticosteroids suffer significant degradation and<br>
Are subject to changes in their surface structure.<br>
Sterilization by P-or y-irradiation is also known. Indeed Illum andMoeller in Arch.<br>
Pharm. Chemi. Sci., Ed. 2,1974, pp. 167-174 recommends the use of such irradiation to<br>
sterilize glucocorticosteroids. However when such irradiation is used to sterilize certain<br>
finely divided, e. g. micronized steroids such as glucocorticosteroids, they are<br>
significantly degraded.<br>
WO-A-96/09814 to Andaris Ltd. relates to spray-dried particles of a water-soluble<br>
material with a mass median partiële size of l to l O, um. The aim of the invention is to<br>
produce smooth and spherical particles for use in dry powder inhalers. The water-soluble<br>
3<br><br>
material is preferably a human protein or a fragment there of in natural or recombinant<br>
forai, e. g. human serum albumin (HSA), alpha-1 antitrypsin or alcohol dehydrogenase.<br>
Also combinations of an active material with a carrier were produced e. g. budesomde<br>
and lactose. It is stated generally that the microparticles produced can be sterile without<br>
teaching how this could or would be neither achieved or showing any proof thereof.<br>
WO-A-96/32095 to Astra AB relates to a process for the preparation of respirable<br>
particles by dissolving an inhalation compound in a solvent introducing the resulting<br>
solution containing the inhalation compound in droplet form or as a Jet stream into an<br>
anti-solvent which is miscible with the solvent and which is under agitation. Budesomde<br>
with a mass median diameter (MMD) of less thanlO um is produced with the process.<br>
There is no Information in WO-A-96/32095 about sterilization or sterile particles.<br>
WQ-A.-92/U280 to Instytut Farmaceutyczny relates. to a method of obtaining, (22R).<br>
diastereoisomer of budesonide by a condensation reactioin followed by crystallizing the<br>
crude product of condensation from ethanol. The obtained 21-acetate of budesonide<br>
(22R) is hydrolyzed and the product thus obtained is crystallized from ethyl acetate. The<br>
content of (22S) diastereoisomer of budesomde isl% or les3- There is no informatión in<br>
WO-92/11280 about sterilization or sterile particles.<br>
A methods for sterilizing biological materials by irradiation over temparaure gradiënt is<br>
discussed in US patent application No.20040033160 by MacPhee at al. US patent<br>
application No. 20040022673 by Protic deals with sterilization process and apparatus<br>
therefor. US patent Application No.20040001774 by Williams at al. (Johnson &amp; Johnson)<br>
discloses sterilization with temperature- controlled diffusion Path. A chemical vapor<br>
sterilization process and system with heat pump operated vaporizer/condenser is<br>
discussed in US patent application No.20040033161 by Kendall et al. (Johnson<br>
&amp;Johnson). High pressure sterilizing of sensitive active pfinciples, particularly peptides,<br>
oligonucleotides and proteins are disclosed in US patent Application No 2003103863 by<br>
Grislain et al.<br>
4<br><br>
We have also found that attempts at terminal sterilization of the pharmaceutical<br>
formulations, especially suspensions, e. g. aqueous suspensions, of glucocorticosteroids<br>
have all proved unsatisfactory. Such suspensions cannot normally be sterilized by sterile<br>
filtration, as most of the particles of glucocorticosteroid will be retained on the filter. We<br>
have also shown that moist heat sterilization, e.g. steam treatment of glass vials<br>
containing the product, leads to an unacceptable change in partiële size.<br>
Various aqueous suspensions of finely divided glucocorticosteroids are known, e.g. the<br>
budesonide-containing product known as Pulmicort# nebulising suspension. (Pulmicort#<br>
is a trademark of Astra AB of Sweden). Similar formulations of fluticasone propionate<br>
are known from WO-A-95/31964.<br>
WO 99/25359 discloses a process for the sterilization of a glucocorticosteroid which<br>
process comprises heat-treating the glucocorticosteroid in the form of a powder at a<br>
temperature of from 100 to!30°C. Although it has been seen that by this method the<br>
formulation shows a considerable rise in impurity levels on stability.<br>
Therefore, there was a need for a new process of sterilization for steroids, which can then<br>
be used in preparation of sterilized formulation.<br>
Object of the invention:<br>
The present invention therefore aims to provide an improved method of sterilization of<br>
steroids involving mixing the steroid along with a surfactant and a vehicle and forming a<br>
wet mass.<br>
Another object of this invention is to provide a method of heat treating this wet mass and<br>
at a particular temperarure-time profile and subsequently sterilizing the said wet mass.<br>
5<br><br>
It is yet another object of this invention to provide a sterilized wet mass which comprises<br>
of the active ingrediënt selected from steroids and such other drugs of this class without<br>
degradation of the active ingrediënt.<br>
The present invention also aims at providing the use of this sterile wet mass, which can<br>
be used in preparations, or formulations, which are required. to be sterile but cannot be<br>
terminally sterilized.<br>
Summary of the invention:<br>
The present invention comprises of a method of steriliza.tion of active pharmaceutical<br>
molecules, that are susceptible to high temperatures; the said method involving forming a<br>
wet mass of the active ingrediënt along with one or more pharmaceutically suitable<br>
excipient and one or more vehicle thereof; the said sterillized mass containinj the<br>
sterilized active ingrediënt thereof and the use of this sterillized mass in preparation of<br>
formulations that are required to be sterile.<br>
Description of Drawing:<br>
Figure l indicates a diagrammatic representation of the process of sterilization. The<br>
pressure vessel (2) contains the wet mass (3) for sterilization xhe pressure vessel (2) is<br>
placed in an Autoclave (1). The wet mass (3) after being sterilized may be transferred to<br>
the bulk solution (not shown in the figure) through the product outlet (4), which is<br>
connected to the vessel containing bulk solution. The pressie vessel (2) is also provided<br>
with air filter housing (5) for release of steam. The pressurt vessel (2) is further provided<br>
with a product filter with housing (6), which may be neces,sary in Order to transfer some<br>
bulk solution to the base solution in order to remove the remaining quantity of base<br>
solution when the pressure in the pressure vessel (2) is low Both the filters (5) and (6)<br>
are provided with 0.22 microns filter in order to maintain stfenlity of the base solution.<br>
6<br><br>
Detailed description:<br>
The present invention describes the method of sterilization of the active pharmaceutical<br>
ingredients, such as steroids that are susceptible to higher temperatures. The method<br>
involves introducing the said active ingrediënt into the pressure vessel or any other sealed<br>
container along with one or more excipient and vehicle. The pressure vessel is fitted with<br>
a hydrophobic vent filter and a hydrophobic cartridge filter. The sterilization is then done<br>
at temperatures ranging from 100-140°C for 3- 30 mins at varying pressure units.<br>
Preferable combinations for temperature-time-pressures are as foJlows:<br>
A.	121oCf or 20 minsa t l5psi.<br>
B.	132°C for 3 mins at 27 psi.<br>
C.	115°C for 30 minutes at 10 psi.<br>
The vessel used for sterilization is a conventional vessel fitted with the attachments such<br>
as a vent filter, cartridge filter and the like, commonly known in the art.<br>
The sterilization of the wet mass when used in formulations results in preparations with<br>
reduced impurities as compared to preparations in which the API was sterilized by other<br>
methods such as Dry heat sterilization, Gamma-radiation sterilization and simply moist<br>
heat sterilization. This is because these molecules are highly susceptible to temperatures<br>
above 60°C. And the sterilization is usually done at temperatures above 100°C. A<br>
comparative impurity profile is as follows:<br><br>
Impurity 	Non- 	F-radiation 	Dry Heat Sterilisation 	Moist <br>
(%) 	sterile 			Heat <br>
		10 	15 	25 	180°C/ 	180°C/ 	180°C/ 	121/3 <br>
		Kgy 	Kgy 	Kgy 	lOmin 	20min 	30mins 	0 <br>
					s 	s 		mins <br>
Predisolone 	ND 	ND 	ND 	ND 	ND 	ND 	ND 	ND <br>
D-Homo 	0.06 	0.07 	0.06 	0.286 	0.06 	0.06 	0.06 	0.05 <br>
7<br><br>
budesonide 						<br><br>
Desonide 	0.10 	0.11 	0.09 	0.044 	0.10 	0.1 	0.09 	0.09 <br>
Predisolone- 	0.02 	0.15 	0.21 	0.062 	0.05 	0.07 	0.07 	0.04 <br>
16-Butyrate 								<br>
21-Dehydro 	ND 	0.10 	0.12 	0.284 	0.07 	0.09 	0.10 	ND <br>
Epimers I and 								<br>
II 								<br>
1,2- 	0.11 	0.12 	0.10 	0.112 	0.11 	0.11 	0.11 	0.16 <br>
DehydroEpime 								<br>
rs I and II 								<br>
Single 	0.04 	0,21 	0.27 	0.182 	0.19 	0.23 	0.26 	0.05 <br>
maximum 								<br>
unknown 								<br>
impurity 								<br>
Total 	0.37 	1.21 	1.42 	1.298 	0.9 	1.03 	1.12 	0.5 <br>
impurities 								<br>
The steroids which may be used in the present invention include but are not limited to<br>
betamethasone, fluticasone (e. g. as propionate), budesonide, tipredane, dexamethasone,<br>
beclomethasone (e. g. as dipropionate), prednisolone, fluocinolone, triamcinolone (e. g.<br>
as acetonide), momethasone (e. g. asfuroate), rofleponide (e. g. as palmitate),<br>
flumethasone, flunisolide, ciclesonide, deflazacort, cortivazol,16a, 17a-butylidenedioxy-<br>
6a, 9a-difluoro-ll ss, 21-dihydroxy-pregna-l,4-diene3,20-dione;6a, 9a-difluoro-ll ss-<br>
hydroxy-16a, 17a-butylidenedioxy-17ss-methylthio- androsta-4-ene-3-one; 16a, 17a-<br>
butylidenedioxy-6a, 9a-difluoro-11 ss-hydroxy-3-oxo- androsta-1,4-diene-17p-<br>
carbothioic acid S-methyl ester; methyl9a-chloro-6a-fluoro-l l ss- hydroxy-16oc-methyl-<br>
3-oxo-17a-propionyloxy-androsta-l} 4-diene-17a-carboxylate; 6a,9a-difluoro-ll ss-<br>
hydroxy-16a-methyI-3-oxo-17a-propionyloxy-androsta-l,4-diene- 17p-carbothioic acid-<br>
(2-oxo-tetrahydrofuran-3-yl) ester; optionally in their pure isomeric forms (where such<br>
forms exist) and/or in the form of their esters, acetals or salts, where applicable. The<br>
8<br><br>
preferred steroids are selected from budesonide, fluticasone, triamcinolone, mometasone,<br>
prednisolone, their salts, solvates, racemic mixtures, enantiomers, prodrugs or isomers<br>
thereof. for use in preparations where the drug must reach the small cavities, such as the<br>
bronchi, the cornea, and such other minute cavities, the active pharmaceutical ingrediënt<br>
may be micronised before sterilization, with the preferred partiële size being d90 less<br>
than 10 microns and more preferably d90 less than 5 microns.<br>
The said excipient may be selected from surfactants which includes polyoxyethylene<br>
esters of sorbitol anhydrides (tweens), the same compounds without the hydrophilic<br>
oxyethylene groups (spans), higher molecuïar weight polyethylene glycols, and<br>
molecular combinations of polyoxyethylene and polyoxypropylenes. The preferred<br>
surfactants are tweens or a combination of tweens and spans. Optionally viscosity<br>
building agents such as sodium carboxy methyl cellulose, polyvinyl alcohol may be used<br>
instead of surfactants.<br>
The said vehicle is water selected from purified water, water for injection or distilled<br>
water, preferably of water for injection grade. The water does not contain any solute,<br>
including any ions, present in the water.<br>
The wet mass can be used in the preparation of the formulations which are required to be<br>
sterile and cannot be sterilized terminally. Such preparations are nasal preparations such<br>
as respules or the aqueous nasal preparations, ophthaJmic preparations and ocular<br>
preparations. The invention is further illustrated with the following example.<br>
Budesonjde respules 0.5 mg:<br><br>
Sr.No 	1 Ingredients 	1 Quantity (%w/v) <br>
r. 	Budesom'de (micronised) 	(—== 	 «i~i 	 	 	 Z__ 	 J<br>
0.025 <br>
2. 	Disodium edetate 	0.01 <br>
3.          ] 	Poiysorbate 80 	0.016 <br>
4. 	Sodium chloride 	0.9 <br>
5- 	Citric acid monohydrate 	q,s. to pH 4 <br>
6. 	Water for Injection 	100 ml <br>
Procedure:<br>
9<br><br>
Preparation of base solution:<br>
1.	Take budesonide along with polysorbate 80 and water for injection in the pressure<br>
vessel.<br>
2.	Sterilize the same by charging in an autoclave at 121 degrees for 30 minutes.<br>
3.	Transfer the sterilized pressure vessel to aseptic area.<br>
Preparation of bulk suspension:<br>
1.	In water for injection cooled under nitrogen purging, add and dissolve sodium<br>
chloride and disodium edetate under stirring.<br>
2.	Adjust the pH of suspension to 4.<br>
3.	Add the base solution from pre-sterilised pressure vessel to the bulk suspension<br>
aseptically.<br>
10<br><br>
We claim,<br>
1.	A method of sterilization of active pharmaceutical ingredients characterized in<br>
that  wet  mass  which  comprises  micronised   active  ingrediënt  along  with<br>
pharmaceutically  acceptable excipient and  one  or more  vehicle  thereof is<br>
subjected to a temperature ranging 100-140°C for 3-30 mins at variable pressure<br>
units.<br>
2.	A   method   of  sterilization   as   claimed   in   claim   l,   wherein   said   active<br>
pharmaceutical ingrediënt are which highly susceptible to temperature above 60°C<br>
are sterilized without effecting their stability.<br>
3.	A   method   of  sterilization   as   claimed   in  claim   l,   wherein   said   active<br>
pharmaceutical ingredients are selected trom the group of steroids and such other<br>
drugs of this class.<br>
4.	A method of sterilization as claimed in claims l to 3S wherein said steroid are<br>
selected  from  but  are  not  limited  to  betamethasone,   fluticasone   (e.g.   as<br>
propionate),  budesonide,  tipredane,  dexamethasone,  beclomethasone  (e.g.  as<br>
dipropionate),  prednisolone,  fluocinolone,  triamcinolone  (e.g.  as  acetonide),<br>
momethasone (e. g. asfuroate), rofleponide (e.g. as palmitate), flumethasone,<br>
flunisolide, ciclesonide, deflazacort, cortivazol,16a, 17a-butylidenedioxy-6a, 9a-<br>
difluoro-11 ss, 21-dihydroxy-pregna-l,4-diene3,20-dione;6a, 9a-difluoro-ll  ss-<br>
hydroxy-16a,    17a-butylidenedioxy-17ss-methylthio-   androsta-4-ene-3-one; 16a,<br>
17a-butylidenedioxy-6a,   9a-difluoro-11   ss-hydroxy-3 -oxo-  androsta-1,4-diene-<br>
17p-carbothioic acid S-methyl ester; methyl9a-chloro-6a-fluoro-ll ss- hydroxy-<br>
16oc-methyl-3 -oxo-17a-propionyloxy-androsta-1,	4-diene-17a-carboxylate;<br>
6a,9a-difluoro-11   ss-hydroxy-16a-methyI-3-oxo-17a-propionyloxy-androsta-1,4-<br>
diene- 17p-carbothioic acid- (2-oxo-tetrahydrofuran-3-yl) ester; optionally in their<br>
pure isomeric forms (where süch forms exist) and/or in the form of their esters,<br>
acetals or salts.<br>
11<br><br>
5.	A method of sterilization as claimed in claim l, wherein preferred steroids are<br>
selected from budesonide, fluticasone, triamcinolone, mometasone, prednisolone,<br>
their salts, solvates, racemic mixtures, enantiomers, prodrugs or isomers thereof.<br>
6.	A method of sterilization as claimed in claim l, wherein the preferred partiële size<br>
of said micronised active pharmaceutical ingrediënt beïng d90 less than 10<br>
microns, more preferably d9Ö less than 5 microns.<br>
7.	A method of sterilization as claimed in claim, l wherein said excipient may be<br>
selected from surfactants which includes polyoxyethylene esters of sorbitol<br>
anhydrides (tweens), the same compounds without the hydrophilic oxyethylene<br>
groups (spans), higher molecular weight polyethylene glycols, and molecular<br>
combinations of polyoxyethylene and polyoxypropylenes and optionally selected<br>
from viscosity  building  agents  such as  sodium carboxy  methyl  cellulose,<br>
polyvinyl alcohol viscosity building agents such as sodium carboxy methyl<br>
cellulose, polyvinyl alcohol.<br>
8.	A method of sterilization as claimed in claim l and 7, wherein the preferred<br>
surfactants are tweens or a combination of tweens and spans.<br>
9.	A method of sterilization as claimed in claim l, wherein said vehicle is water,<br>
selected from purifled water, water for injection or distilled water, preferably<br>
water for injection grade.<br>
10.	A method of sterilization as claimed in claim l, wherein the water is not saturated<br>
with respect to any solute, including ions, present in the water.<br>
11.	A method of sterilization as claimed in any of the preceding claims wherein said<br>
sterilization is conducted at 121°C for 20 mins at 15psi.<br>
12<br><br>
13<br>
12.	A method of sterilization as claimed in any of the preceding claims wherein said<br>
sterilization is conducted at 115°C for 30 mins at l0psi.<br>
13.	A method of sterilization as claimed in any of the preceding claims wherein said<br>
sterilization is conducted at 132°C for 3 mins at 27psi.<br>
14.	A process for making an aqueous sterile pharmaceutical formulation, the said<br>
process comprises placing a wet mass comprising the steroid, an excipient and<br>
water in a pressure vessel or any other sealed container which in turn is placed in<br>
an autoclave, heat treating the wet mass to sterilize the steroid and directly<br>
transferring the sterilized mass to the remaining bulk of the formulation.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWFic3RyYWN0KDExLTMtMjAwNSkuZG9j" target="_blank" style="word-wrap:break-word;">313-mum-2004-abstract(11-3-2005).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWFic3RyYWN0KDExLTMtMjAwNSkucGRm" target="_blank" style="word-wrap:break-word;">313-mum-2004-abstract(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUFCU1RSQUNUKEdSQU5URUQpLSgxOC01LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-MUM-2004-ABSTRACT(GRANTED)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNBTkNFTExFRCBQQUdFUyg5LTUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CANCELLED PAGES(9-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWNsYWltcygxMS0zLTIwMDUpLmRvYw==" target="_blank" style="word-wrap:break-word;">313-mum-2004-claims(11-3-2005).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWNsYWltcygxMS0zLTIwMDUpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-claims(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNMQUlNUyhBTUVOREVEKS0oOS01LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CLAIMS(AMENDED)-(9-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNMQUlNUyhHUkFOVEVEKS0oMTgtNS0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CLAIMS(GRANTED)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNMQUlNUyhNQVJLRUQgQ09QWSktKDktNS0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CLAIMS(MARKED COPY)-(9-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWNvcnJlc3BvbmRlbmNlKDEwLTMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">313-mum-2004-correspondence(10-3-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNPUlJFU1BPTkRFTkNFKDE3LTQtMjAwNikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CORRESPONDENCE(17-4-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNPUlJFU1BPTkRFTkNFKDIxLTItMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CORRESPONDENCE(21-2-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUNPUlJFU1BPTkRFTkNFKElQTyktKDE4LTUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-CORRESPONDENCE(IPO)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWNvcnJlc3BvbmRlbmNlKGlwbyktKDQtMy0yMDA1KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-correspondence(ipo)-(4-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWRlc2NyaXB0aW9uKGNvbXBsZXRlKS0oMTEtMy0yMDA1KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-description(complete)-(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LURFU0NSSVBUSU9OKEdSQU5URUQpLSgxOC01LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-MUM-2004-DESCRIPTION(GRANTED)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWRlc2NyaXB0aW9uKHByb3Zpc2lvbmFsKS0oMTItMy0yMDA0KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-description(provisional)-(12-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWRyYXdpbmcoMTEtMy0yMDA1KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-drawing(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LURSQVdJTkcoR1JBTlRFRCktKDE4LTUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-DRAWING(GRANTED)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMSgxMi0zLTIwMDQpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 1(12-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMSgyNS0zLTIwMDQpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 1(25-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMTgoMTAtMy0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 18(10-3-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMigxMS0zLTIwMDUpLmRvYw==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 2(11-3-2005).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMigxMS0zLTIwMDUpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 2(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUZPUk0gMihHUkFOVEVEKS0oMTgtNS0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">313-MUM-2004-FORM 2(GRANTED)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMihwcm92aXNpb25hbCktKDEyLTMtMjAwNCkuZG9j" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 2(provisional)-(12-3-2004).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMihwcm92aXNpb25hbCktKDEyLTMtMjAwNCkucGRm" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 2(provisional)-(12-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMih0aXRsZSBwYWdlKS0oMTEtMy0yMDA1KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 2(title page)-(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUZPUk0gMihUSVRMRSBQQUdFKS0oR1JBTlRFRCktKDE4LTUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-FORM 2(TITLE PAGE)-(GRANTED)-(18-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMih0aXRsZSBwYWdlKS0ocHJvdmlzaW9uYWwpLSgxMi0zLTIwMDQpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 2(title page)-(provisional)-(12-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMjUoMTEtMy0yMDA1KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 25(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMjYoMTItMy0yMDA0KS5wZGY=" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 26(12-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUZPUk0gMjYoOS01LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-MUM-2004-FORM 26(9-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMygxMi0zLTIwMDQpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 3(12-3-2004).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gMygyLTUtMjAwNSkucGRm" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 3(2-5-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUZPUk0gMygyNC0xMC0yMDExKS5wZGY=" target="_blank" style="word-wrap:break-word;">313-MUM-2004-FORM 3(24-10-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LUZPUk0gMyg5LTUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">313-MUM-2004-FORM 3(9-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLW11bS0yMDA0LWZvcm0gNSgxMS0zLTIwMDUpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-mum-2004-form 5(11-3-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LVBFVElUSU9OIFVOREVSIFJVTEUtMTM3KDktNS0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">313-MUM-2004-PETITION UNDER RULE-137(9-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVCgyNC0xMC0yMDExKS5wZGY=" target="_blank" style="word-wrap:break-word;">313-MUM-2004-REPLY TO EXAMINATION REPORT(24-10-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzEzLU1VTS0yMDA0LVJFUExZIFRPIEhFQVJJTkcoOS01LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">313-MUM-2004-REPLY TO HEARING(9-5-2012).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="252489-an-apparatus-for-supplying-energy-to-energy-bus-in-a-hybrid-electric-vehicle.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="252491-iontophoretic-preparation-for-treatment-of-breast-cancer-and-or-mastitis.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>252490</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>313/MUM/2004</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>21/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>25-May-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>18-May-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>12-Mar-2004</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>CIPLA LIMITED</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>289, BELLASIS ROAD, MUMBAI CENTRAL, MUMBAI-400008</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>LULLA AMAR</td>
											<td>131, MAKER TOWER-L 13th FLOOR, CUFFE PARADE COLABA,MUMBAI-400015</td>
										</tr>
										<tr>
											<td>2</td>
											<td>MALHOTRA GEENA</td>
											<td>4, ANDERSON HOUSE, OPP. MAZGAON POST OFFICE, MAZGAON, MUMBAI-400010</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61L</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td></td>
									<td></td>
								    <td>NA</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/252490-method-of-sterilization by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:20:06 GMT -->
</html>
